← SynDRA
PURMORPHAMINE
SynDRA canonical compound SYN0023970 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | SMO |
|---|
| Mechanism of action | Smoothened receptor agonist |
|---|
All known targets
Mechanisms of action (all sources)
- Smoothened receptor agonist
- SMO AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2C9
- GAMT
- GNMT
- HNMT
- IFNG
- KSYK
- NNMT
- PNMT
- SYK
Cross-references
Synonyms
- PB12M2F8KY
- CHEBI:63053
- RefChem:177303
- DTXCID10366144
- Shh Signaling Antagonist VI
- 2-(1-Naphthoxy)-6-(4-morpholinoanilino)-9-cyclohexylpurine
- Purmorphamine [MI]
- Purmorphamine (GMP)
- MFCD09037557
- 2-(1-Napthoxy)-6-(4-morpholinoanilino)-9-cyclohexylpurine
- UNII-PB12M2F8KY
- Purmorphamine?
- C31H32N6O2
- MolMap_000073
- MLS006010334
- orb1307399
- SCHEMBL1548273
- SCHEMBL29358352
- GTPL10356
- EX-A348
- FYBHCRQFSFYWPY-UHFFFAOYSA-N
- GLXC-06182
- HMS3650O20
- HMS3651D16
- BDBM50324671
- HB3412
- HSCI1_000224
- HY-15108G
- NSC747596
- s3042
- AKOS024458218
- CCG-269857
- CS-1135
- FP27264
- NSC-747596
- SB19498
- NCGC00344053-01
Look up PURMORPHAMINE in the interactive SynDRA portal →